Good morning :)
Place Order
Add to Watchlist

Mankind Pharma Ltd

MANKIND

Mankind Pharma Ltd

MANKIND
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,06,841 cr, stock is ranked 85
Moderate RiskStock is 2.37x as volatile as Nifty
2,680.700.50% (+13.35)
2,680.700.50% (+13.35)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,06,841 cr, stock is ranked 85
Moderate RiskStock is 2.37x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹1,06,841 cr, stock is ranked 85
Moderate RiskStock is 2.37x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
54.4411.16
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.446.570.51%

Forecast & Ratings

Detailed Forecast 
79%
Analysts have suggested that investors can buy this stock

from 14 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue5,987.196,397.067,992.048,890.4210,630.8410,986.81
Raw Materialssubtract1,888.532,028.002,871.322,622.903,263.378,087.56
Power & Fuel Costsubtract79.9682.53103.13108.96129.30
Employee Costsubtract1,335.531,415.781,620.591,918.472,274.73
Selling & Administrative Expensessubtract885.851,086.441,410.011,616.921,880.42
Operating & Other expensessubtract237.29-47.44-214.04580.25250.37
Depreciation/Amortizationsubtract99.06118.97166.62325.92398.25418.64
Interest & Other Itemssubtract23.2421.1659.8045.7635.0538.10
Taxes & Other Itemssubtract407.31426.19541.12389.39486.46479.98
EPS25.7231.5935.7832.0047.7548.99
DPS0.007.600.000.000.000.00
Payout ratio0.000.240.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 2PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Mankind Pharma Ltd55.8511.16
Sun Pharmaceutical Industries Ltd46.316.610.73%
Cipla Ltd30.404.670.84%
Torrent Pharmaceuticals Ltd65.4215.810.87%

Price Comparison

Compare MANKIND with any stock or ETF
Compare MANKIND with any stock or ETF
MANKIND
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding74.87%6.99%2.91%12.37%2.86%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep3.92%3.90%7.55%8.57%7.37%6.99%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Mankind Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
SBI Blue Chip Fund - Growth - Direct Plan

Growth
0.6623%1.33%0.11%34/60 (-5)
Axis ELSS Tax Saver Fund - Growth - Direct Plan

Growth
0.2783%0.76%-0.07%32/93 (+16)
SBI FUNDS MANAGEMENT PVT LTD#SBI MF-SBI CONTRA FUND DIRECT PL GROWTH

Growth
0.2506%0.65%-0.01%86/113 (-6)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Mankind Pharma Ltd

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Spotlight
Mankind Pharma Ltd spurts 3.89%

Mankind Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 2729.95, up 3.89% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.6% on the day, quoting at 24194.3. The Sensex is at 79405.35, down 0.67%. Mankind Pharma Ltd has risen around 5.86% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has risen around 2.54% in last one month and is currently quoting at 22374.95, up 1.48% on the day. The volume in the stock stood at 1.53 lakh shares today, compared to the daily average of 2.98 lakh shares in last one month.The PE of the stock is 56.17 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 day agoCapital Market - Live
Corporate
Mankind Pharma to convene board meeting

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Mankind Pharma receives ratings action from ICRA

Mankind Pharma has received reaffirmation in credit rating for non-convertible debentures (Rs 4,600 crore) at ICRA AA+; Stable. The company has been assigned the rating ICRA A1+ and ICRA AA+; Stable for commercial papers (Rs 5,000 crore), non-convertible debentures (Rs 400 crore) and bank facilities (Rs 1,250 crore). Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Mankind Pharma Ltd soars 3.76%

Mankind Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 2631.1, up 3.76% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.3% on the day, quoting at 25867.5. The Sensex is at 84684.03, up 0.17%. Mankind Pharma Ltd has risen around 11.82% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has risen around 2.38% in last one month and is currently quoting at 23005.25, up 0.37% on the day. The volume in the stock stood at 6.1 lakh shares today, compared to the daily average of 6.37 lakh shares in last one month.The PE of the stock is 54.44 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Mankind Pharma hits record high after board OKs to raise Rs 10,000 cr

The company will raise funds by way of issuance of non-convertible debentures (NCDs) and Commercial Papers (CPs) on private placement basis for an amount aggregating upto Rs 10,000 crore. The board has also constituted and authorized the Fund Raising Committee to take all necessary actions including finalization of the terms of issuance, allotment of NCDs and CPs and other related matters. Meanwhile, the company's board also approved corporate guarantees for its subsidiaries, Mankind Agritech Private, Appian Properties, Copmed Pharmaceuticals Private and Lifestar Pharma LLC. Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. The pharmaceutical company reported 10.19% increase in consolidated net profit to Rs 536.49 crore in Q1 FY25 as against Rs 486.87 crore posted in Q1 FY24.Revenue from operations stood at Rs 2,893.42 crore in Q1 FY25, up 12.20% as against with Rs 2,578.62 crore in Q1 FY24. The scrip hit all-time high at Rs 2,645 in intraday today.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Mankind Pharma board OKs to raise Rs 10,000 cr

The company will raise funds by way of issuance of non-convertible debentures (NCDs) and Commercial Papers (CPs) on private placement basis for an amount aggregating upto Rs 10,000 crore. The board has also constituted and authorized the Fund Raising Committee to take all necessary actions including finalization of the terms of issuance, allotment of NCDs and CPs and other related matters. Meanwhile, the company's board also approved corporate guarantees for its subsidiaries, Mankind Agritech Private, Appian Properties, Copmed Pharmaceuticals Private and Lifestar Pharma LLC. Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. The pharmaceutical company reported 10.19% increase in consolidated net profit to Rs 536.49 crore in Q1 FY25 as against Rs 486.87 crore posted in Q1 FY24.Revenue from operations stood at Rs 2,893.42 crore in Q1 FY25, up 12.20% as against with Rs 2,578.62 crore in Q1 FY24. The counter rallied 4.78% to ends at Rs 2,547.15 on Friday, 20 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Live Market Update
Sensex, Nifty hit new life highs; bank shares rally for 5th day

The key equity indices traded with minor gains in mid-morning trade. The Nifty scaled above the 25,450 level. Bank shares extended gains for the fifth consecutive trading session. At 11:30 IST, the barometer index, the S&P BSE Sensex was up 163.21 points or 0.19% to 83,242.56. The Nifty 50 index rose 32.50 points or 0.13% to 25,451.05. The Sensex and Nifty clocked an all-time high of 83,310.32 and 25,478.60, respectively in morning trade. In the broader market, the S&P BSE Mid-Cap index fell 0.32% and the S&P BSE Small-Cap index shed 0.02%. The market breadth was weak. On the BSE, 1,749 shares rose and 2,002 shares fell. A total of 166 shares were unchanged. IPO Update : The initial public offer (IPO) of Western Carriers (India) received bids for 22,71,20,112 shares as against 2,08,68,467 shares on offer, according to stock exchange data at 11:15 IST on Wednesday (18 September 2024). The issue was subscribed 10.88 times. The issue opened for bidding on Friday (13 September 2024) and it will close on Thursday (19 September 2024). The price band of the IPO is fixed between Rs 163 to Rs 172 per share. An investor can bid for a minimum of 87 equity shares and in multiples thereof. The initial public offer (IPO) of Northern Arc Capital received bids for 28,00,14,210 shares as against 2,14,78,290 shares on offer, according to stock exchange data at 11:15 IST on Wednesday (18 September 2024). The issue was subscribed 13.04 times. The issue opened for bidding on Monday (16 September 2024) and it will close on Thursday (19 September 2024). The price band of the IPO is fixed between Rs 249 to 263 per share. An investor can bid for a minimum of 57 equity shares and in multiples thereof. The initial public offer (IPO) of Arkade Developers received bids for 46,95,66,350 shares as against 2,37,75,719 shares on offer, according to stock exchange data at 11:15 IST on Wednesday (18 September 2024). The issue was subscribed 19.75 times. The issue opened for bidding Monday (16 September 2024) and it will close on Thursday (19 September 2024). The price band of the IPO is fixed between Rs 121 to 128 per share. An investor can bid for a minimum of 110 equity shares and in multiples thereof. Buzzing Index : The Nifty Bank index rose 0.90% to 52,684.70. The index advanced 3.28% in the five consecutive trading sessions. Bandhan Bank (up 1.85%), HDFC Bank (up 1.56%), State Bank of India (up 1.14%), ICICI Bank (up 0.76%) and IndusInd Bank (up 0.52%), Kotak Mahindra Bank (up 0.5%), Axis Bank (up 0.49%), Punjab National Bank (up 0.2%) edged higher. On the other hand, IDFC First Bank (down 1.2%), AU Small Finance Bank (down 0.17%) and Federal Bank (down 0.1%) edged lower. Stocks in Spotlight : Mankind Pharma fell 0.55%. The pharma major informed that a meeting of its board is scheduled to be held on Friday, 20 September 2024 to mull the fund raising proposal for an amount as may be decided. GPT Infraprojects declined 1.14%. The said that it has bagged a contract worth Rs 204 crore for construction of road over bridge from CAO Construction, South Eastern Railway, Kolkata. Global Markets : Most Asian shares traded higher on Wednesday as investors await the Federal Reserve's rate decision due Wednesday stateside and assessed economic data from Japan. Indonesian central bank's rate decision is also due later in the day. While Chinese markets remained relatively stable after resuming trading from an extended break, investors also looked ahead to the Bank of Japan's policy meeting later in the week. The BoJ is expected to maintain current interest rates but may adopt a more hawkish stance, signaling potential future rate hikes. Japan's imports and exports in August rose 2.3% and 5.6%, respectively, from a year ago, according to Japan's Ministry of Finance. In the United States, stock markets closed mixed on Tuesday as uncertainty persisted regarding the magnitude of the Federal Reserve's anticipated rate cut. The Dow Jones Industrial Average fell 0.04% while the S&P 500 rose 0.3%, reversing momentum from earlier in the day, when they were at or near record levels. The Nasdaq Composite, meanwhile, finished higher by 0.2%. Market participants are widely expecting the Fed to reduce interest rates, with opinions divided between a 25 or 50 basis point cut. However, bets on a larger 50 basis point reduction have been gaining momentum. Additionally, the Fed's announcement is anticipated to signal the beginning of an easing cycle, which is generally positive for risk-oriented stock markets. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Mankind Pharma to conduct board meeting

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 20 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Mankind Pharma board to consider fund raising on Sep 20

The company will raise funds through issue of non-convertible debentures, commercial papers, other debt securities or any other security or any combination thereof. Mankind pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence.Mankind pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. The pharmaceutical company reported 10.19% increase in consolidated net profit to Rs 536.49 crore in Q1 FY25 as against Rs 486.87 crore posted in Q1 FY24.Revenue from operations stood at Rs 2,893.42 crore in Q1 FY25, up 12.20% as against with Rs 2,578.62 crore in Q1 FY24. Shares of Mankind Pharma shed 0.22% to Rs 2,448.05 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Stock Alert : Mankind Pharma, AU Small Finance Bank, VST Industries, Cupid, Texmaco Rail & Infra Engg

Securities in F&O ban: Aditya Birla Fashion and Retail, Balrampur Chini Mills, Hindustan Copper New Listing: ECOS (India) Mobility & Hospitality will debut on the bourses today. The issue was open between 28 August and 30 August 2024. The price band of the IPO was between Rs 318 to 334 per share. The issue was subscribed 64.26 times. Stocks to watch: Mankind Pharma has executed a Business Transfer Agreement to transfer its over-the-counter (OTC) business undertaking on a slump sale basis to its subsidiary, Mankind Consumer Products (MCPPL). NHPC has signed a memorandum of Understanding (MoU) with the Department of Water Resources (WRD), Maharashtra Government, for the establishment of energy storage systems (pumped storage systems) along with other renewable energy sources (such as solar/wind/hybrid) with a total capacity of 7,350 MW. PDS' facilities in Bangladesh have resumed normal operations, and normalcy has returned across its partner factories in the region. The company remains positive about medium-term business prospects in Bangladesh. AU Small Finance Bank has submitted an application to Reserve Bank of India (RBI) seeking approval for a voluntary transition from small finance bank to universal bank. Cupid is looking to expand its B2C pie substantially moving forward. It aims to achieve the topline target in excess of Rs 50 crore in FY25. The company is also planning to partner with Blinkit and Zepto for better e-commerce presence. It also plans to launch almond hair oil in four SKUs among other products this month. Torrent Power has entered into a fresh MoU with the Department of Water Resources, Government of Maharashtra, for the establishment of pumped storage projects with a total capacity of 5,600 MW instead of 5,700 MW. Texmaco Rail &Infra Engineering has completed the acquisition of Jindal Rail & Infrastructure, strengthening its position in the wagons market and expanding its capabilities and product range. The final cash payment was Rs 614 crore, at a valuation of 8.1 times the FY24 EV/Ebitda. VST Industries has received in-principle approval from BSE and NSE for the issuance and proposed allotment of 15 crore equity shares as bonus shares. The bonus shares will be issued in a 10:1 ratio.Powered by Capital Market - Live

1 month agoCapital Market - Live